Shots:

• Cipla acquires Venus’ anti-infective products- Elores to robust its presence in Indian critical care space as a part of its agenda to contribute to the fight against Anti-Microbial Resistance (AMR)
• The acquisition will underscore Cipla’s commitment to anti-microbial stewardship and strengthen its branded anti-infectives portfolio in India with the addition of Elores and its prior acquisition of Zemdtrim
• Elores is a novel combination of Ceftriaxone- Sulbactam and Disodium EDTA indicated to treat life-threatening infectious diseases caused by gram-negative bacteria- preserving the efficacy of antibiotics utilizing ARBs

Click here to­ read full press release/ article | Ref: Cipla | Image: Dalaal Street Investment Journal